Oncolytics Biotech (ONCY) PT Lowered to $5 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ONCY Hot Sheet
Price: $0.42 +7.69%
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Canaccord Genuity analyst John Newman lowered the price target on Oncolytics Biotech (NASDAQ: ONCY) to $5.00 (from $6.00) while maintaining a Buy rating.
You May Also Be Interested In
- Oncolytics reports pelareorep HPV immune response data in anal cancer
- United Therapeutics Corp. (UTHR) PT Raised to $720 at Raymond James
- Datadog (DDOG) PT Lowered to $260 at BTIG
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
